Becton Dickinson to licence Med-Design's safety needle:
This article was originally published in Clinica
Becton Dickinson has gained exclusive licensing rights to Med-Design's retractable needle technology, which prevents accidental needlestick injuries. The deal will provide Med-Design, Ventura, California, with a multi-million dollar up-front payment and royalties. Becton will also make a $1.5 million equity investment in Med-Design through the purchase of 300,000 shares at $5 per share. Becton will be entitled to one seat on Med-Design's board.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.